HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund A USD Cap

Reference Data

ISIN LU1540961759
Valor Number 35003342
Bloomberg Global ID
Fund Name HBM UCITS (Lux) Funds-HBM Global Biotechnology Fund A USD Cap
Fund Provider HBM Partners AG Zug, Schweiz
Phone: +41 43 888 71 71
E-Mail: investorrelations@hbmpartners.com
Web: www.hbmpartners.com
Fund Provider HBM Partners AG
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) S.A.
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved.
Peculiarities

Fund Prices

Current Price * 409.40 USD 16.04.2025
Previous Price * 413.52 USD 15.04.2025
52 Week High * 509.65 USD 08.11.2024
52 Week Low * 384.79 USD 08.04.2025
NAV * 409.40 USD 16.04.2025
Issue Price * 409.40 USD 16.04.2025
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 18,826,315
Unit/Share Assets *** 3,718,663
Trading Information SIX

Performance

YTD Performance -9.70% 31.12.2024
16.04.2025
YTD Performance (in CHF) -19.11% 31.12.2024
16.04.2025
1 month -11.15% 17.03.2025
16.04.2025
3 months -9.78% 16.01.2025
16.04.2025
6 months -17.36% 16.10.2024
16.04.2025
1 year -4.06% 16.04.2024
16.04.2025
2 years +0.34% 17.04.2023
16.04.2025
3 years +2.76% 20.04.2022
16.04.2025
5 years -2.28% 22.04.2020
16.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

argenx SE 7.98%
Gilead Sciences Inc 4.75%
Vertex Pharmaceuticals Inc 4.14%
Amgen Inc 4.02%
Zealand Pharma AS 3.83%
Regeneron Pharmaceuticals Inc 3.66%
Alnylam Pharmaceuticals Inc 3.63%
Insmed Inc 3.55%
Ascendis Pharma AS ADR 3.54%
Neurocrine Biosciences Inc 3.51%
Last data update 31.12.2024

Cost / Risk

TER 0.0238%
TER date 31.01.2018
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 2.13%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)